

Transforming Early Autism Diagnosis with Objective, Eye-Tracking Technology

EarliPoint® Health is the **first and only FDA-cleared technology** that measures a child's visual attention to identify and quantify core characteristics of autism as early as 16 months.



Earlier, More Objective Evaluation

- EarliPoint analyzes over 120 eye-tracking data points per second while a child watches brief videos of social interaction.
- The platform provides quantitative insights into social-visual attention, giving clinicians an objective complement to behavioral observation.
- Enables evaluation at 16–95 months, when early identification can dramatically improve developmental outcomes through therapies such as Applied Behavior Analysis (ABA).



Clinically Proven Accuracy & Reliability

Based upon pooled analysis of 3 studies (reference Jones, W. et al. Eye-Tracking-Based Measurement of Social Visual Engagement Compared With Expert Clinical Diagnosis of Autism. JAMA 2023.), EarliPoint demonstrated:

- AUC = 0.90 for distinguishing autism from non-autism.
- 80.6% sensitivity and 87.0% specificity, comparable to best practice, gold-standard evaluation.
- Strong individual correlation with multi-hour expert clinical assessments of social disability (e.g., ADOS) and of verbal and nonverbal abilities.
- Evidence-based, objective tool to aid in early autism diagnosis, based on >25 years of scientific research published in top-tier peer-reviewed journals (JAMA, JAMA Network Open, Nature, Proceedings of the National Academy of Sciences, Archives of General Psychiatry, American Journal of Psychiatry, among others).

Seamless Integration into Pediatric Care

- Qualified providers offer coordinated diagnostic services using EarliPoint, reducing wait times for families while ensuring high clinical standards.
- Objective results enhance referral decisions and facilitate shared care planning between pediatricians, specialists, and families.
- Supports data-driven follow-up and ongoing assessments to measure progress over time.

To review the research, including two clinical trials published in JAMA (2023), please visit: www.earlipointhealth.com.



 1-833-504-9937

 info@earlipointhealth.com

The EarliPoint Assessment device is indicated as a tool to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder (ASD) in children ages 16 months through 95 months (7 years), who are at risk based on concerns identified by a parent, caregiver, or healthcare provider.